Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
26/09/2024 | 14:51 | GlobeNewswire Inc. | Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing | NASDAQ:AZN | AstraZeneca PLC |
26/09/2024 | 13:00 | Business Wire | TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer | NASDAQ:AZN | AstraZeneca PLC |
23/09/2024 | 13:00 | Business Wire | Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
23/09/2024 | 12:44 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
23/09/2024 | 12:32 | IH Market News | Apollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and More | NASDAQ:AZN | AstraZeneca PLC |
20/09/2024 | 22:34 | Business Wire | FLUMIST approved for self-administration in the US | NASDAQ:AZN | AstraZeneca PLC |
18/09/2024 | 13:00 | Business Wire | FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis | NASDAQ:AZN | AstraZeneca PLC |
17/09/2024 | 17:22 | GlobeNewswire Inc. | International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 | NASDAQ:AZN | AstraZeneca PLC |
16/09/2024 | 13:00 | Business Wire | IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
15/09/2024 | 16:30 | Business Wire | IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
13/09/2024 | 16:00 | Business Wire | ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases | NASDAQ:AZN | AstraZeneca PLC |
10/09/2024 | 16:28 | PR Newswire (US) | SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing | NASDAQ:AZN | AstraZeneca PLC |
10/09/2024 | 12:02 | IH Market News | Apple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9% | NASDAQ:AZN | AstraZeneca PLC |
09/09/2024 | 19:50 | Business Wire | Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
08/09/2024 | 18:25 | Business Wire | Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
05/09/2024 | 12:11 | IH Market News | Qualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual Listing | NASDAQ:AZN | AstraZeneca PLC |
03/09/2024 | 13:00 | Business Wire | AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024 | NASDAQ:AZN | AstraZeneca PLC |
23/08/2024 | 14:20 | IH Market News | Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1% | NASDAQ:AZN | AstraZeneca PLC |
16/08/2024 | 13:00 | Business Wire | IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery | NASDAQ:AZN | AstraZeneca PLC |
15/08/2024 | 13:00 | Business Wire | IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US | NASDAQ:AZN | AstraZeneca PLC |
30/07/2024 | 12:00 | IH Market News | Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots | NASDAQ:AZN | AstraZeneca PLC |
29/07/2024 | 13:00 | Business Wire | Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
25/07/2024 | 13:00 | Business Wire | AstraZeneca’s H1 and Q2 2024 Financial Results | NASDAQ:AZN | AstraZeneca PLC |
25/07/2024 | 12:21 | IH Market News | U.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire Expectations | NASDAQ:AZN | AstraZeneca PLC |
25/07/2024 | 12:19 | IH Market News | Earnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5% | NASDAQ:AZN | AstraZeneca PLC |
23/07/2024 | 13:00 | PR Newswire (Canada) | Voydeya est approuvé au Canada à titre de traitement d'appoint au ravulizumab ou à l'éculizumab chez les adultes atteints d'une maladie rare, appelée HPN, qui présentent une anémie hémolytique résiduelle attribuable à une hémolyse extravasculair | NASDAQ:AZN | AstraZeneca PLC |
23/07/2024 | 13:00 | PR Newswire (Canada) | Voydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia due to extravascular hemolysis | NASDAQ:AZN | AstraZeneca PLC |
25/06/2024 | 13:00 | Business Wire | IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
17/06/2024 | 13:00 | Business Wire | IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer | NASDAQ:AZN | AstraZeneca PLC |
16/06/2024 | 13:00 | Business Wire | CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial | NASDAQ:AZN | AstraZeneca PLC |